Jones Financial Companies Lllp Takes Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Jones Financial Companies Lllp acquired a new position in Elanco Animal Health Incorporated (NYSE:ELANFree Report) during the fourth quarter, Holdings Channel.com reports. The firm acquired 2,513 shares of the company’s stock, valued at approximately $37,000.

Several other institutional investors have also recently made changes to their positions in the business. KBC Group NV raised its stake in shares of Elanco Animal Health by 18.2% during the 4th quarter. KBC Group NV now owns 130,952 shares of the company’s stock valued at $1,952,000 after buying an additional 20,143 shares during the last quarter. Bank of Nova Scotia purchased a new position in Elanco Animal Health during the fourth quarter valued at approximately $4,004,000. TFO Wealth Partners LLC lifted its holdings in Elanco Animal Health by 103,300.0% in the fourth quarter. TFO Wealth Partners LLC now owns 43,428 shares of the company’s stock valued at $626,000 after acquiring an additional 43,386 shares during the period. Innealta Capital LLC acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $209,000. Finally, TD Asset Management Inc lifted its stake in shares of Elanco Animal Health by 20.4% in the 4th quarter. TD Asset Management Inc now owns 331,585 shares of the company’s stock valued at $4,941,000 after purchasing an additional 56,266 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 1.0 %

Shares of ELAN opened at $18.27 on Friday. Elanco Animal Health Incorporated has a 52-week low of $8.52 and a 52-week high of $18.65. The stock has a market cap of $9.03 billion, a PE ratio of -6.89, a price-to-earnings-growth ratio of 1.76 and a beta of 1.45. The firm’s fifty day moving average is $15.47 and its two-hundred day moving average is $15.06. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.95.

Elanco Animal Health (NYSE:ELANGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.08. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. Elanco Animal Health’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.45 earnings per share. Research analysts forecast that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. The Goldman Sachs Group lifted their price target on Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research note on Tuesday, February 27th. Barclays boosted their price objective on Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. Piper Sandler reiterated a “neutral” rating and set a $19.00 target price (up previously from $18.00) on shares of Elanco Animal Health in a research report on Monday, May 13th. Finally, TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.29.

View Our Latest Report on Elanco Animal Health

Insider Activity

In related news, Director William F. Doyle acquired 15,000 shares of the stock in a transaction on Tuesday, May 21st. The shares were bought at an average price of $16.98 per share, with a total value of $254,700.00. Following the completion of the purchase, the director now owns 76,330 shares of the company’s stock, valued at approximately $1,296,083.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANFree Report).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.